USPTO hurting recovery?

The Journal Sentinel Online in Milwaukee, Wisconsin published an interesting series of articles on the present state of the United States Patent and Trademark Office. 

The articles discuss the present backlog of pending patent applications and the potential effect on present economic recovery, the rise in rejections of patent applications in the name of quality, and employee turnover at the USPTO.

Patent backlog clogs recovery.

Patent rejections soar as pressure on agency rises.

Turnover troubles agency.

David Kappos to the rescue?

Troutman Sanders Adds Five New IP Attorneys, Creates Life Sciences Practice Team

Troutman Sanders LLP is pleased to announce the addition of seven intellectual property lawyers who have joined the firm’s newly created Life Sciences practice team.

The new attorneys in the firm's New York office are Albert L. Jacobs Jr.Gerard F. Diebner, Daniel A. Ladow, Magnus Essunger and Timothy M. Salmon.  Prior to joining Troutman Sanders, the five worked most recently for the boutique IP law firm of Albert Jacobs LLP in New York, where Jacobs was chairman and managing partner.

Continue Reading...

David Kappos - New Director of the USPTO

The new Under Secretary of Commerce for Intellectual Property and Director of the USPTO David Kappos was sworn in on August 13, 2009.

Click here for a description of Kappo's background provided by the USPTO on their web site.

Click here for Kappos' remarks at the swearing in ceremony.

And PatentlyO.com printed a recent email of Kappos to patent examiners which states that "patent quality does not equal rejection":

His positive statements should be encouraging to all inventors and patent applicants.  Stay tuned for more change.

Clarifying patent infringement of "Product by Process" claims

In Abbott Labs. v. Sandoz, Ins. (“Abbott”), an en banc Court of Appeals for the Federal Circuit has clarified its own previously issued inconsistent holdings on determining infringement of product-by-process claims. 

Historically, product-by-process claims have been limited to claims in chemical patents and were originally used to claim products that could not be analyzed to determine their precise chemical composition. The inventor knows how he made it and what it does, but not exactly what it is.  If a chemical product cannot be precisely defined except by the process that produces it, a claim to such a product defined by its method of preparation is proper. Manual of Patent Examining Procedure § 706.03(e). The so-called "product-by-process" format utilizes process limitations to define the composition. Despite the process limitations, the claim has always been considered a “product” or “composition of matter” claim by the USPTO and not a “process” claim. The USPTO defines a product-by-process claim as a product claim in which the product is defined, in whole or in part, by the process used to make the product. 

 

The applicability of the product-by-process claim with modern laboratory analytics is limited, but still may be appropriate in some cases.  However, patent practitioners still often include a product-by-process claim in a case with other structurally defined product claims. This use of the product-by-process claims is outside the original intent of the claim format.  There should be an either/or situation, either you can define the product structurally or you can only define it by the process used to make it, not both. However, practitioners feel adding a product-by-process claim to in addition to the structurally defined claim may broaden patent protection and more easily capture infringers.

 

In Abbott, the CAFC clarified the test for infringement of product-by-process claims. There was uncertainty due to previous CAFC holdings; in Atlantic Thermoplastics, the CAFC held that to infringe a product-by-process claim the accused infringer must have performed all the process steps defined in the claim, however, in Scripps the CAFC stated that the process steps were not important in determining infringement, the court should only consider whether the accused product infringed the claim regardless of the process steps performed to prepare the product. Reasonable minds can disagree, but when the reasonable minds are the decision makers, uncertainty results. 

 

The en banc panel in Abbott held that to infringe a product-by-process claim, you must infringe the process steps and the product is irrelevant to the infringement analysis. Therefore, while determining infringement is based upon the process limitations, the USPTO continues to determine patentability of product-by-process claims based upon the product.

Continue Reading...

Will Exergen and Iqbal Lead to More Rigorous Pleading Requirements in Patent Cases?

Last week’s decision by the Federal Circuit regarding the pleading requirements for an inequitable conduct claim, Exergen Corp. v. Wal-Mart Stores, Inc., 2009 U.S. App. LEXIS 17311 (Fed. Cir. Aug. 4, 2009), and the Supreme Court’s decision earlier this summer in Ashcroft v. Iqbal, 129 S.Ct. 1937 (2009) may foreshadow additional enhanced pleading requirements in patent infringement cases. 

Robert Matthews at Mathews Patent-Law Consulting has published a detailed analysis of Exergen that can be found here. In short, under Fed.R.Civ.P. 9, a claim of inequitable conduct must include specific identification of the who, what, when, where and how of the material misrepresentation committed before the PTO. As Matthews states, under Exergen, “an accused infringer must identify the exact information within a withheld prior art reference that it alleges is material, identify where that information can be found in the reference, identify the particular claim limitations or combination of claim limitations for which the withheld information is material, and then show how the prosecution record lacked that information.” 

An accused infringer must also identify by name the specific individual who allegedly knew of the allegedly material information and withheld or misrepresented that information to the PTO. A party may plead “on information and belief” but only if essential information lies within another party’s control and only if the pleading sets forth specific facts upon which the belief is reasonably based. Thus, the mere fact that an applicant disclosed a reference while prosecuting one application but did not disclose the same reference while prosecuting a second application is insufficient to plead the requirement of deceptive intent. 

Exergen echoes the Supreme Court’s decisions in Iqbal and Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) that under Fed.R.Civ. P. 8, a pleading offering “labels and conclusions” or a “formulaic recitation of a cause of action will not do.” As the Court stated in Iqbal, “While legal conclusions can provide the framework of a complaint, they must be supported by factual allegations.” Thus, a plaintiff must make “well-pleaded factual allegations” that “plausibly give rise to an entitlement to relief.” 

Exergen takes Iqbal and Twombly a step further, requiring allegation of facts with a high degree of specificity and detail, and Exergen may presage stricter pleading requirements for other types of patent claims and defenses. 

So far, though, the Federal Circuit has not required stricter pleading of patent infringement claims. Applying Twombly, the Federal Circuit has held that a claim for patent infringement must only assert that the plaintiff owns the patent and that the defendant infringed the patent, must describe, in general terms, “the means by which the patent was infringed” and must identify the specific parts of patent law that are implicated. McZeal v. Sprint Nextel Corp., 501 F.3d 1354, 1357 (Fed. Cir. 2007). A patentee “is not required to specifically include each element of the claims of the asserted patent." Thus, here in Virginia, Judge Payne has held that a plaintiff satisfies McZeal by identifying the infringing devices at issue. Taltwell, LLC v. Zonet USA Corp., 2007 U.S. Dist. LEXIS 93465 at *40 (E.D.Va. Dec. 20, 2007).  Judge Dyk dissented in McZeal, arguing that a patentee should be required to specify which claims are infringed and the features of the accused device that correspond to the claim limitations, and Iqbal arguably supports Judge Dyk’s position. At this point, though, it appears that the Federal Circuit will not impose stricter requirements for pleading patent infringement, even though a plaintiff’s Rule 11 obligations requires a detailed infringement analysis before suit is filed and such information often must be provided in a claim chart filed early in the case.